Graham Lumsden and Peter Hanson today announced the formation of VetrixBio, a biotechnology company focused on developing novel therapies for companion animals.
VetrixBio was founded on a simple premise: pets deserve better medicine. Millions of dogs and cats live with chronic conditions that are often underdiagnosed, undertreated, or managed with limited options. The company’s mission is to develop therapies that not only relieve symptoms, but meaningfully improve quality of life and long-term outcomes.
“We see a clear opportunity to bring the advances of human biotechnology into veterinary medicine,” said Graham Lumsden. “The science has progressed significantly, and applying that progress to animal health can open up entirely new treatment possibilities.”
VetrixBio’s approach centers on translating clinically validated targets and therapeutic modalities into animal health. Working with its partners, the company utilizes advanced discovery and engineering platforms, including large libraries of canine-derived antibodies and protein scaffolds, to identify and optimize candidates with strong binding affinity and functional activity.
“Our focus is on applying the rigor of human drug development to veterinary care,” said Peter Hanson. “That includes how we discover therapies, how we design them, and how we think about delivering them in a way that works in practice.”
The company is also utilizing computational biology and precision protein engineering to enable targeted, localized delivery of therapies. By designing molecules that bind directly to diseased tissue, VetrixBio aims to achieve higher local concentrations for effect while reducing systemic exposure and off-target effects.
VetrixBio is a biotechnology company focused on developing novel biologic therapies for companion animals. Guided by the belief that pets deserve better medicines, the company is advancing a pipeline targeting osteoarthritis and cancer—two of the most significant unmet needs in veterinary medicine. VetrixBio’s approach centers on translating advances in biologics and immunotherapy into practical treatments designed to improve outcomes and quality of life for dogs and cats. Led by an experienced team spanning biotechnology, animal health, and commercialization, and supported by a network of scientific and clinical advisors, VetrixBio is committed to bringing the next generation of veterinary medicines to market.
VetrixBio, Inc.
47 Enon St., Unit 7, Suite 127
Beverly, MA 01915
info@vetrixbio.com
This press release contains forward-looking statements, including statements regarding the development, potential efficacy, and future progress of VetrixBio’s product candidates. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. VetrixBio undertakes no obligation to update these statements except as required by law.
